GlaxoSmithKline And Genmab Announce Results From A Study Of Arzerra In Rituximab Refractory Follicular NHL

LONDON and COPENHAGEN, Denmark -- Summary: GSK and Genmab announce top-line results from a study of Arzerra (ofatumumab) in rituximab refractory follicular NHL. GlaxoSmithKline (GSK) and Genmab A/S announced today top-line results from an international multi-center study of Arzerra(TM) (ofatumumab) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL). A total of 116 patients were treated in the study, including 30 patients treated with 500 mg ofatumumab and 86 patients treated with 1000 mg of ofatumumab. The patients in the study were highly refractory. Forty-nine percent of patients were refractory to their last chemotherapy treatment. Patients in the study had previously received a median of 4 prior treat...